Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis
By
Yanshuo Shi
Xin Xu
Yuanyuan Yue
Jianqun Zhao
Kaiqing Yao
Huizhen Wu
June 29, 2026
Clinical Scorecard: Efficacy and Safety of Dipyridamole, Immunoglobulin, and Aspirin Combination Therapy for Kawasaki Disease in Pediatric Patients: A Meta-Analysis
At a Glance
Category Detail
Condition Kawasaki Disease Key Mechanisms Dipyridamole exhibits antiplatelet, anti-inflammatory, and coronary vasodilating effects. Target Population Pediatric patients under 8 years of age diagnosed with Kawasaki Disease. Care Setting Clinical treatment involving randomized controlled trials.
Key Highlights
Dipyridamole combined with immunoglobulin and aspirin shows superior efficacy compared to immunoglobulin and aspirin alone. Significant improvement in clinical symptoms and laboratory indicators in the observation group. No significant difference in adverse reactions between the two treatment groups. Guideline-Based Recommendations
Diagnosis
Diagnosis based on American Heart Association criteria for Kawasaki Disease. Management
Treatment with immunoglobulin and aspirin, with dipyridamole as an additional therapy for resistant cases. Monitoring & Follow-up
Monitor clinical symptoms and laboratory indicators such as CRP, ESR, PLT, CAL, and FIB. Risks
Approximately 10% of patients may exhibit IVIG resistance or aspirin intolerance. Patient & Prescribing Data
Children diagnosed with Kawasaki Disease who have not received prior treatment.
Initial immunoglobulin dosage of 2 g/(kg·d) and aspirin 25 to 50 mg/(kg·d), with dipyridamole added at 5 mg/(kg·d) for the observation group.
Clinical Best Practices
Initiate treatment within 10 days of disease onset. Evaluate treatment efficacy based on total effective rate and laboratory indicators. Related Resources & Content
